U.S. Life Sciences Stock News

Recent Performance Snapshot Medpace Holdings (MEDP) has attracted attention after recent share price moves, with the stock up about 2.5% over the past day, 5.9% over the past week, and 8.1% over the past month. See our latest analysis for Medpace Holdings. That short term 1 day share price return of 2.5% and 1 month share price return of 8.1% sit against a 90 day share price decline of 17.1% and a 1 year total shareholder return of 83.4%. This suggests momentum has picked up again after a...

In recent days, Pinnacle West Capital has gained attention as one of the best utility dividend payers, while also advancing Arizona nuclear license renewal efforts and preparing to report its first-quarter 2026 results in early May after already releasing those figures. This combination of dividend focus and nuclear expansion potential is drawing interest to a company whose underlying operations and financial condition are still viewed as relatively weak and risky. We’ll now examine how...

Analyst coverage sparks fresh look at Dutch Bros Telsey’s new coverage of Dutch Bros (BROS), with a positive view on its loyalty program, comparable sales, and planned store expansion, has put the fast growing drive through coffee chain back on many investors’ radar. See our latest analysis for Dutch Bros. At a share price of US$53.03, Dutch Bros has recently seen a 7 day share price return of 4.68% and a 30 day share price return of 3.35%. Its 90 day share price return of 16.11% and 1 year...

Linde (LIN) is back in focus after William O'Neil initiated coverage, highlighting its strong market position, a reported US$10b project backlog, and ties to areas like clean hydrogen and semiconductor manufacturing. See our latest analysis for Linde. The recent 13.92% 90-day share price return and 21.27% 1-year total shareholder return suggest momentum has been building, as investors respond to Linde’s new US facility plans and the announcement of first quarter 2026 results. If you are...

A recent flood-related washout near Coloma forced CSX to shut down its rail line between Chicago and Grand Rapids, halting both freight operations and Amtrak’s Pere Marquette passenger service while repairs to the undermined track bed proceed. This disruption highlights how extreme weather can quickly strain rail reliability and raise short-term costs for infrastructure owners like CSX, even on well-used corridors. We’ll now examine how this weather-driven line shutdown, and the repair...

Fermi (FRMI) is back in focus after securing up to US$156.25 million in committed financing through a new senior unsecured promissory note, alongside recent equipment loans and fresh clean air permit applications for large scale power projects. See our latest analysis for Fermi. Despite announcing large financing facilities and expanded clean air permit applications, Fermi’s recent share price return has been weak. The 30 day share price return is 38.33% and the year to date share price...

Herbalife recently issued Q1 and full-year 2026 net sales growth guidance, projecting reported net sales to increase between 3.0% and 7.0% year over year for Q1 and 1.0% to 6.0% for 2026, prompting analysts to reassess the company’s turnaround prospects. The shift in analyst fair value estimates to US$16.50 highlights how updated guidance and evolving views on Herbalife’s turnaround are reshaping expectations for its business performance. We’ll now examine how Herbalife’s newly issued 2026...

Garmin’s Natural Cycles integration: what it could mean for the stock Garmin (GRMN) is drawing fresh attention after announcing a product integration with Natural Cycles, the FDA cleared birth control and fertility app, on select smartwatch models across multiple major markets. This partnership brings overnight skin temperature tracking from compatible Garmin devices directly into the Natural Cycles app, expanding Garmin’s women’s health capabilities and potentially strengthening the appeal...

AXIS Capital Holdings stock context AXIS Capital Holdings (AXS) has drawn investor attention after a period of mixed share performance, with the stock showing a 1 day decline of 0.38% and a past month decline of 1.90%. Over the past 3 months, AXIS Capital Holdings has recorded a 2.09% decline, while the 1 year total return stands at 16.11%, set against a market value of about US$7.5b. See our latest analysis for AXIS Capital Holdings. AXIS Capital Holdings’ recent 1 day and 3 month share...

In recent weeks, Agilent Technologies secured FDA approval for an expanded PD-L1 IHC 22C3 pharmDx cancer companion diagnostic indication and introduced the BioTek Cytation 9 cell imaging multimode reader, while the U.S. Supreme Court let stand rulings invalidating two of its CRISPR-related patents. This combination of a broader clinical diagnostic role alongside a new high-content lab instrument launch, set against a legal setback in gene-editing IP, reshapes how investors may view Agilent’s...

Assessing Deckers Outdoor after a mixed share price run Deckers Outdoor (DECK) has had a mixed share price run lately, with a 1 day decline, a modest gain over the past week, and negative returns over the month and past 3 months, prompting a closer look at fundamentals. See our latest analysis for Deckers Outdoor. At a share price of $100.26, Deckers Outdoor has seen recent share price pressure, with a 30 day share price return of 3.83% and a year to date share price return of 6.11%. Longer...

BioCryst Pharmaceuticals (BCRX) is in focus after appointing Sandeep M. Menon as Chief Research and Development Officer, a leadership change that directly ties to its rare disease pipeline and longer term R&D priorities. See our latest analysis for BioCryst Pharmaceuticals. At a share price of $9.59, BioCryst has seen a 30 day share price return of 13.09% and year to date share price return of 27.87%, while the 1 year total shareholder return of 48.22% points to building momentum around...

Flowers Foods (FLO) has drawn fresh attention after a series of executive moves, including CEO share sales, leadership departures, and wider organizational reshaping, alongside mixed results that combined higher sales with a net loss. See our latest analysis for Flowers Foods. The recent executive reshuffle and CEO share sale have come against a weak share price backdrop, with a 30 day share price return of 10.77% and a 1 year total shareholder return of 50.05% pointing to fading momentum as...

Covista Inc. recently expanded Michael Betz’s role to Chief Growth & Innovation Officer, adding oversight of the Marketing organization while he remains President of Walden University and leader of the Digital organization. This consolidation of growth, innovation, and marketing under a single leader marks a material shift in how Covista aims to coordinate its education brands and digital capabilities following the departure of Chief Marketing Officer Maurice Herrera. We’ll now examine how...

In March 2026, Sportradar AG announced it had expanded its multi-year agreement with Hard Rock Bet in the U.S., adding official PGA TOUR and UFC data, enhanced odds, and richer in-play betting features powered by assets gained through its IMG ARENA acquisition. The deeper tie-up showcases how Sportradar is bundling premium data rights with advanced visualizations and micro markets to become more embedded in operators’ core betting experiences. We’ll now examine how this expanded Hard Rock...

Life Time Group Holdings (LTH) is in focus after opening Life Time Eagle, its first athletic country club in Idaho. The 135,000-square-foot facility extends the brand into the Boise area. See our latest analysis for Life Time Group Holdings. The latest Idaho opening comes as momentum in the shares has picked up, with a 1 month share price return of 11.15% and a 3 year total shareholder return of 63.95%, suggesting sentiment has strengthened over time. If this kind of expansion has your...

The Professional Women’s Hockey League just set a U.S. attendance record for women’s hockey with a sold-out debut at Madison Square Garden, highlighting fresh demand for ice events at Madison Square Garden Sports (MSGS). See our latest analysis for Madison Square Garden Sports. The sold out PWHL debut comes at a time when MSGS has already seen strong momentum, with a 90 day share price return of 25.4% and a 1 year total shareholder return of 82.64%. This suggests investors are responding...

Event-driven look at Cohu stock Cohu (COHU) is back on investor radars after announcing US$30 million in follow on orders for its Eclipse test platform, which is configured with active thermal control for next generation high performance computing processors. One of these customers is also taking a subscription to Cohu’s PAICe prescriptive analytics software. This carries potential annual fees of about US$330,000 and ties recurring software revenue directly to equipment performance and...

Zimmer Biomet Holdings (ZBH) has drawn investor attention after recent trading left the stock with mixed returns, including a loss over the past year despite modest year to date gains. See our latest analysis for Zimmer Biomet Holdings. The recent 1 day share price return of 0.44% to US$91.40 and a modest 7 day gain sit against a 1 year total shareholder return decline of about 10%, indicating fading longer term momentum despite short term stability. If Zimmer Biomet’s move toward robotics...

Why Bristow Group’s latest quarter caught the market’s eye Bristow Group (VTOL) drew attention after reporting year on year revenue growth of 6.7%, while falling short of analysts’ expectations on EBITDA and EPS for the quarter. The company also highlighted continued expansion in its Government Services business, which management says is helping position Bristow as a multi mission aviation services provider with established roles in its core regions. See our latest analysis for Bristow...

Celsius Holdings (CELH) is back in focus after acquiring Rockstar Energy and Alani Nu, with analysts turning more positive as management points to revenue growth and potential margin gains during the ongoing integration. See our latest analysis for Celsius Holdings. The recent acquisitions and strong revenue print have not yet translated into share price strength. A 30 day share price return of 19.66% and a 90 day share price return of 32.84% have contributed to a year to date share price...

Wondering if Main Street Capital at around US$53.99 is offering fair value or a premium price today? This article breaks down what that number really means for you. The stock has a 1.9% return over the last 7 days, a 5.9% decline over 30 days, is down 12.6% year to date, and shows an 18.0% return over 1 year, 75.5% over 3 years and 90.0% over 5 years. Taken together, this gives a mixed picture of recent momentum and longer term performance. Recent coverage has focused on how Main Street...

In late March 2026, Denali Therapeutics announced that the FDA granted accelerated approval for AVLAYAH, the first blood-brain-barrier-crossing biologic for treating neurologic manifestations of Hunter syndrome in eligible pediatric patients, while in early April 2026 it received notice that Takeda will end their DNL593 co-development agreement, returning all rights and future obligations to Denali. Together, these developments highlight Denali’s transition toward independently advancing its...

In March 2026, BlackSky Technology Inc. was awarded a multi-year, sole-source US$99 million U.S. government IDIQ contract from the Air Force Research Laboratory to design advanced large-aperture optical payloads for next-generation Earth observation and space domain awareness satellites. The contract highlights BlackSky’s role in developing satellites that act as in-orbit data storage and processing hubs compatible with AI-enabled space data centers, potentially expanding its relevance...